Roivant Sciences (NASDAQ:ROIV) Hits New 12-Month High – Should You Buy?

Roivant Sciences Ltd. (NASDAQ:ROIV)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $35.95 and last traded at $35.5250, with a volume of 654 shares. The stock had previously closed at $35.39.

Analyst Ratings Changes

Several analysts have issued reports on ROIV shares. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Guggenheim lifted their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, TD Cowen upped their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Roivant Sciences Stock Performance

The company has a market cap of $25.33 billion, a P/E ratio of -58.63 and a beta of 1.11. The firm has a 50 day moving average price of $30.38 and a 200-day moving average price of $27.39.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The firm had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. During the same period in the previous year, the company earned ($0.29) EPS. On average, sell-side analysts forecast that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Insider Activity

In other Roivant Sciences news, CEO Matthew Gline sold 289,774 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the transaction, the chief executive officer owned 16,736,116 shares of the company’s stock, valued at $488,025,142.56. This represents a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Jennifer Humes sold 13,538 shares of the firm’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the transaction, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. This trade represents a 13.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 2,359,225 shares of company stock worth $77,401,516. Insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. raised its holdings in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in Roivant Sciences in the 4th quarter valued at $47,000. Parallel Advisors LLC grew its position in Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares during the period. Finally, CIBC Private Wealth Group LLC grew its position in Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after acquiring an additional 2,665 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.